Advances toward a cure for HIV: getting beyond n=2.

Abstract

Achieving a cure for HIV remains a priority in HIV research. Two cases of 'sterilizing cure' have been observed-in Timothy Ray Brown and the "London" patient; both patients received allogeneic hematopoietic stem cell transplantation (HSCT) from donors homozygous for the CCR5-delta 32 deletion, which impairs function of an HIV coreceptor on host cells. Other strategies that have been evaluated for achieving sterilizing cure or functional cure--ie, sustained virologic remission in the absence of antiretroviral therapy (ART)-include: HSCT with wild-type CC chemokine receptor (CCR5); early ART to limit size of the HIV latent reservoir; shock and kill strategies using latency reversing agents and/or anti-HIV broadly neutralizing antibodies; and gene therapy, including attempts to modify CCR5 genes, HIV proviruses in autologous host cells, or enhanced T cells. This article summarizes a presentation by Jonathan Li, MD, MMSc, at the International Antiviral Society-USA (IAS-USA) continuing education program held in Atlanta, Georgia, in March 2019.

• Authors: Jonathan Li
• Journal: Topics in antiviral medicine (Top Antivir Med) Vol. 27 Issue 4 Pg. 91-95 (Jan 2020) ISSN: 2161-5853 [Electronic] United States
• PMID: 32224499 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Receptors, CCR5

Topics

• Antiviral Agents (immunology, therapeutic use)
• CD4-Positive T-Lymphocytes (drug effects, immunology, virology)
• HIV Infections (drug therapy, immunology, virology)
• HIV-1 (immunology)
• Hematopoietic Stem Cell Transplantation
• Humans
• Receptors, CCR5 (immunology)
• Secondary Prevention
• Virus Latency